5IU Stock Overview
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Isofol Medical AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.048 |
| 52 Week High | kr0.089 |
| 52 Week Low | kr0.023 |
| Beta | 1.53 |
| 1 Month Change | -7.82% |
| 3 Month Change | 11.03% |
| 1 Year Change | 25.78% |
| 3 Year Change | -96.04% |
| 5 Year Change | n/a |
| Change since IPO | -96.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5IU | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.0% | 2.1% | -1.0% |
| 1Y | 25.8% | -22.2% | 2.0% |
Return vs Industry: 5IU exceeded the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: 5IU exceeded the German Market which returned 2% over the past year.
Price Volatility
| 5IU volatility | |
|---|---|
| 5IU Average Weekly Movement | 21.8% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5IU's share price has been volatile over the past 3 months.
Volatility Over Time: 5IU's weekly volatility has decreased from 27% to 22% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 3 | Petter Lindqvist | isofolmedical.com |
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm.
Isofol Medical AB (publ) Fundamentals Summary
| 5IU fundamental statistics | |
|---|---|
| Market cap | €9.64m |
| Earnings (TTM) | -€3.18m |
| Revenue (TTM) | €61.92k |
155.7x
P/S Ratio-3.0x
P/E RatioIs 5IU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5IU income statement (TTM) | |
|---|---|
| Revenue | kr721.00k |
| Cost of Revenue | kr35.14m |
| Gross Profit | -kr34.41m |
| Other Expenses | kr2.66m |
| Earnings | -kr37.07m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -0.23 |
| Gross Margin | -4,773.23% |
| Net Profit Margin | -5,141.61% |
| Debt/Equity Ratio | 0% |
How did 5IU perform over the long term?
See historical performance and comparison